In 2015 I was invested in a different biotech stock that did a reverse split and uplisted. It didn’t take long for institutions to scoop up millions of shares and help the overall market cap of the stock to rise. Their drug was in a phase 2a at the time.

My point is this: I have little doubt that there are a number of institutions that would like to buy into CYDY. And the fact is they can’t by in until CUDY uplists.